Novotech Report Analyses Epilepsy Research Trends Finding More than 4,000 Clinical Trials Conducted Globally
June 20 2024 - 10:58PM
Novotech Report Analyses Epilepsy Research Trends Finding More than
4,000 Clinical Trials Conducted Globally
Novotech, the global full-service clinical Contract Research
Organization (CRO) that partners with biotech companies to
accelerate the development of advanced and novel therapeutics at
every phase, has released a comprehensive research report entitled
Epilepsy - Global Clinical Trial Landscape.
Drawing on Novotech’s extensive expertise and global network
this report presents a data-backed review of the epilepsy funding
landscape, trial density and patient recruitment data across
geographies, standard of care and emerging therapies, recent USFDA
approvals, and regulatory trends. Importantly it also includes an
in-depth SWOT analysis, to guide biotech firms on strategic
decision-making, and research opportunities, and challenges.
Epilepsy, a chronic neurological disorder affecting individuals
of all ages and characterized by recurrent seizures, affects an
estimated 46 million people worldwide.
The report sheds light on the distribution of epilepsy cases
across different regions, highlighting hotspots such as South Asia,
East Asia, and sub-Saharan Africa.
Despite ongoing research efforts, the cause of epilepsy remains
unknown in 50% of cases, presenting a significant challenge in
treatment and management, as well as research targets for the
biotech sector. However, with appropriate antiepileptic
medications, up to 70% of individuals can achieve seizure-free
status.
The Epilepsy - Global Clinical Trial Landscape report found that
in the past 5 years the global biopharma sector has initiated more
than 4,000 clinical trials for epilepsy.
- Asia-Pacific has the majority of epilepsy trials at 35%
- Europe and North America are at 30% and 27% respectively
- ROW is 8%
- China (30%), Germany (8%) and the United States (72%) led
clinical trial initiation within their respective regions
The report provides insights into the standard of care for
epilepsy, emphasizing the role of anticonvulsant therapy in seizure
management. From monotherapy to non-pharmacological interventions
such as ketogenic diets and neurostimulation devices, the report
outlines comprehensive approaches to epilepsy treatment,
considering factors such as patient demographics, comorbidities,
and therapeutic efficacy.
The rise of drug-resistant epilepsy has also spurred innovation
with recent research focusing on tailored therapies, new drug
targets, and non-pharmacological interventions. Advancements in
technology have led to novel strategies such as Neurostimulation
devices like Responsive Neurostimulation (RNS), Vagus Nerve
Stimulation (VNS), and Deep Brain Stimulation (DBS), offering
alternatives for non-responsive patients.
Further key findings from the report include:
- Trial Density: The Asia-Pacific region
exhibits a lower competing trial risk, indicating the potential for
increased research engagement in the region.
- Patient Recruitment Landscape: Single-country
trials in the Asia-Pacific region have shown shorter median
recruitment durations and faster recruitment rates compared to the
United States and Europe, emphasizing the region's efficiency in
conducting clinical trials.
- Drug Discovery Landscape: With 46 drugs in
preclinical stages, 19 in Phase I, 21 in Phase II, and 7 in Phase
III, the epilepsy drug development pipeline demonstrates promising
advancements in treatment options.
- SWOT Analysis: Finds a range of challenges and
opportunities such as drug-resistant epilepsy, quality of life of
patients, ongoing research focus of biomarkers, and advancements in
research and technology.
Venture capital funding for epilepsy research showed a positive
trend from 2019 to 2023 with the United States topping the list,
contributing $1555.3 million, followed by Switzerland, China, South
Korea, and Singapore contributed $214.4 million, $213.0 million,
$75.2 million, and $18.0 million, respectively.
The Novotech research analyst team provides these expert reports
on a monthly basis, completely free of charge. These reports offer
current insights into global clinical trial activity, revealing
which regions experience the highest trial volumes and the unique
factors behind these trends. They tackle the potential and real
hurdles faced by biotech firms in specific therapeutic areas in the
hopes to positively impact and inform clinical trial decision
making, eventually improving rates of success with new
treatments.
Download the report here
About Novotech
Novotech-CRO.com
Founded in 1997, Novotech is a global full-service clinical
Contract Research Organization (CRO) focused on partnering with
biotech companies to accelerate the development of advanced and
novel therapeutics at every phase.
Recognized for its industry-leading contributions, Novotech has
received numerous prestigious awards, including the CRO Leadership
Award 2023, the Asia Pacific Cell & Gene Therapy Clinical
Trials Excellence 2023, the Asia-Pacific Contract Research
Organization Company of the Year Award since 2006.
The Company offers a comprehensive suite of services including
laboratories, Phase I facilities, drug development consulting,
regulatory expertise, and has experience with over 5,000 clinical
projects, including Phase I to Phase IV clinical trials and
bioequivalence studies. With a presence in 34 office locations and
a dedicated team of 3,000+ professionals worldwide, Novotech is a
trusted end-to-end strategic partner of choice.
For more information or to speak to an expert team member
visit www.Novotech-CRO.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/66424c7f-1b7e-4158-bfe1-46f78622eaa9